Healthcare, Pharma & Life Sciences

FDA Grants Orphan Drug Status to Lundbeck's Cushing's Antibody Asedebart

Valby, Denmark – – September 17, 2026 -- The U.S. Food and Drug Administration has granted Orphan Drug Designation to asedebart (Lu AG13909), Lundbeck's investigational anti-ACTH monoclonal antibody, for the treatment of endogenous Cushing's syndrome.

FDA designation adds U.S. market exclusivity potential for Lundbeck's rare disease pipeline

The designation covers drugs and biologics intended for rare diseases and can provide tax credits for qualified clinical testing, exemption from certain FDA application fees, and up to seven years of market exclusivity if the drug is approved for the designated indication.

Missouri Law HB 2974 Speeds Licensing, Expands Telehealth Access

Image
Missouri Law HB 2974 Speeds Licensing, Expands Telehealth Access

Kansas City, Mo. – September 17, 2026 -- Missouri Governor Mike Kehoe joined nonpartisan think tank United WE at its Kansas City headquarters on September 10 for a ceremonial signing of House Bill 2974, a law that shortens licensing wait times for out-of-state professionals and clarifies telehealth rules for providers with reciprocal Missouri licenses. The bill was formally signed on July 13 and took effect August 28.

HB 2974 resolves ambiguity blocking telehealth providers from treating Missouri patients

The law confirms that a health care provider granted a Missouri license based on an out-of-state credential is fully licensed in the state, including for delivering care to Missouri patients via telehealth. The previous statute, in place since 2018, had left that question unresolved.

Radiologist Lori Lee Barr Named 2026 Top Pinnacle Healthcare Professional

Pensacola, Fla. – September 17, 2026 -- Lori Lee Barr, MD, FACR, FAIUM, a partner at Radiology Associates of Florida, P.A., has been named a 2026 Top Pinnacle Healthcare Professional by The Inner Circle for her work in radiology, the organization announced.

Dr. Barr holds dual board certification in pediatric and diagnostic radiology

Dr. Barr is a Diplomate of the American Board of Radiology, one of 24 specialty boards under the American Board of Medical Specialties. She earned her medical degree from Louisiana State University School of Medicine at Shreveport and completed her diagnostic radiology residency and pediatric radiology fellowship at the University of Texas Medical Branch at Galveston. The American College of Radiology and the American Institute of Ultrasound in Medicine have recognized her as a fellow for teaching, research, clinical care and community advocacy.

MegazoneCloud Builds AI QA Agent for Hanmi Pharmaceutical

Seoul -- September 17, 2026 -- MegazoneCloud has begun system development on 'Hanmi Q-Agent,' an AI agent designed to cut Hanmi Pharmaceutical's quality assurance document workload by more than 40%, with build work starting September 7.

MegazoneCloud deploys RAG-based agent across 4,000 quality documents

The Seoul-based AI and cloud company will build a search-based AI agent covering roughly 4,000 quality documents accumulated by Hanmi Pharmaceutical, using its enterprise AI OS 'AIR Studio.' The retrieval-augmented generation (RAG) system will retrieve and summarize documents, then compare them against the latest pharmaceutical regulations to flag non-conforming items.

Galien Foundation Launches First Prix Galien Japan Awards in Tokyo

Image
Galien Foundation Launches First Prix Galien Japan Awards in Tokyo

Tokyo – September 17, 2026 -- The Galien Foundation will hold the inaugural Prix Galien Japan Forum and Awards Ceremony on Thursday, September 17, 2026, at the Hotel New Otani in Tokyo, marking the first time the life sciences prize has been presented in Japan.

Six award categories will honor pharmaceutical, biotech and digital health innovators

The ceremony will present awards across six categories: Best Pharmaceutical Product, Best Biotechnology Product, Best Product for Rare/Orphan Diseases, Best Medical Technology, Best Digital Health Solution, and Best Startup. Winners will be selected by the Prix Galien Japan Awards Committees, made up of biomedical scientists and industry executives from Japan and abroad.

CSL Seqirus Publishes Phase 3 Data on Triple-Technology Flu Vaccine in Lancet

Maidenhead, United Kingdom – September 17, 2026 -- CSL Seqirus has published pivotal Phase 3 results for its MF59-adjuvanted, cell-based, higher-dose quadrivalent influenza vaccine (aQIVc) in The Lancet Infectious Diseases, reporting superiority over an adjuvanted egg-based comparator across all four influenza strains and age groups tested in a 7,699-participant trial.

Trial enrolled nearly 7,700 adults aged 50 and older across eight countries

The randomised, observer-blind study recruited participants in Canada, Denmark, Estonia, Germany, Pakistan, the Philippines, the United Kingdom and the United States, comparing aQIVc against an MF59-adjuvanted egg-based quadrivalent vaccine and a recombinant quadrivalent vaccine. The vaccine met its primary objectives, showing non-inferiority versus the recombinant comparator for three of four strains in the 50-plus group and four of four strains in those aged 65 and above.

Experts Issue First Global Consensus on Type 1 Diabetes Screening

Image
Experts Issue First Global Consensus on Type 1 Diabetes Screening

New York – September 17, 2026 -- A consensus paper published in Diabetologia establishes the first international framework for population-wide screening of type 1 diabetes (T1D), setting concrete age thresholds and testing protocols for clinical adoption.

Nearly 30 global experts define screening ages and intervals

The guidance, convened by Breakthrough T1D and developed by close to 30 international experts, recommends initial autoantibody screening for children aged 2-4 years. Children who test negative should be rescreened at ages 6-8 and again at 10-15, timed to align with routine preventative healthcare visits. Initial positive results require confirmation with a second test before diagnosis is made.

TransCode Therapeutics CFO Tom Fitzgerald Retires, John Tattory Named Interim CFO

Image
TransCode Therapeutics CFO Tom Fitzgerald Retires, John Tattory Named Interim CFO

Boston – September 17, 2026 -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) said Chief Financial Officer Tom Fitzgerald is retiring, effective immediately, and will be succeeded on an interim basis by John Tattory.

Fitzgerald exits after eight years steering TransCode through IPO and acquisitions

Fitzgerald has served as CFO since July 2018, a tenure spanning the company's initial public offering, the launch of clinical development for lead candidate TTX-MC138, the acquisition of Polynoma, and a license agreement with Oncolytics. He resigns as CFO and as a company director effective immediately but will remain to provide transition services.

Chairman and CEO Philippe P. Calais credited Fitzgerald with keeping the company funded from its early discovery-stage days. "Tom has worked tirelessly to keep us funded and on track," Calais said.

Cardiol Therapeutics Files US$150M Shelf Prospectus, Expands OSC Disclosure

Image
Cardiol Therapeutics Files US$150M Shelf Prospectus, Expands OSC Disclosure

Toronto – September 17, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has filed a preliminary short form base shelf prospectus in Canada and a corresponding Form F-10 registration statement with the U.S. SEC, enabling the life sciences company to raise up to US$150 million over a 25-month period.

Shelf filing permits future issuance of shares, debt and warrants

The filings, made under the U.S./Canada Multijurisdictional Disclosure System, would allow Cardiol to offer Class A common shares, debt securities, warrants, subscription receipts, units, or combinations thereof, once a final receipt is issued and the Registration Statement becomes effective. No securities are being offered under this announcement, and the Company said there is no assurance an offering will occur.

AAKP Inducts Arkansas Advocate Bob Abbott Into Hall of Fame

Image
AAKP Inducts Arkansas Advocate Bob Abbott Into Hall of Fame

Little Rock, Arkansas – September 17, 2026 -- The American Association of Kidney Patients (AAKP) inducted Pine Bluff advocate Bob Abbott into its newly created Kidney Advocate Hall of Fame on September 10, opening the organization's 51st annual National Patient Meeting in Little Rock, Arkansas.

AAKP launches inaugural Hall of Fame class at Clinton Presidential Center

The induction ceremony took place during AAKP's Policy Forum session at the William J. Clinton Presidential Center, recognizing Abbott alongside medical experts, federal officials, and researchers as part of the Hall of Fame's first cohort. AAKP's tribute cited more than five decades of advocacy work by Abbott, owner and manager of Abbott Enterprises Inc. in Pine Bluff.